Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan-Reference-Cited by-同舟云学术

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan

Published:2023 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Toyoda Kazunori¹,Arakawa Shuji²,Ezura Masayuki³,Kobayashi Rei⁴,Tanaka Yoshihide⁵,Hasegawa Shu⁶,Yamashiro Shigeo⁷,Komatsu Yoji⁸,Terasawa Yuka⁹,Masuno Tomohiko¹⁰,Kobayashi Hiroshi¹¹,Oikawa Suzuko¹²,Yasaka Masahiro¹³

Affiliation:

1. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center

2. Department of Neurology, Steel Memorial Yawata Hospital

3. National Hospital Organization Sendai Medical Center

4. Department of Neurology, National Hospital Organization Nagoya Medical Center

5. Yokosuka Kyosai Hospital

6. Department of Neurosurgery, Japanese Red Cross Kumamoto Hospital

7. Division of Neurosurgery, Department of Cerebrovascular Medicine and Surgery, Saiseikai Kumamoto Hospital

8. Department of Neurosurgery, Hitachi General Hospital

9. Brain Attack Center Ota Memorial Hospital

10. Nippon Medical School Hospital

11. Research and Development, Alexion, AstraZeneca Rare Disease

12. Research and Development, Bristol Myers Squibb

13. Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64223/_pdf

Reference30 articles.

1. 1) Takagi M, Tanaka K, Miwa K, Sasaki M, Koga M, Hirano T, Kamiyama K, Yagita Y, Nagakane Y, Hoshino H, Terasaki T, Yakushiji Y, Kudo K, Ihara M, Yoshimura S, Yamaguchi Y, Shiozawa M, Toyoda K and BAT2 Investigators: The bleeding with antithrombotic therapy study 2: Rationale, design, and baseline characteristics of the participants. Eur Stroke J, 2020; 5: 423-431

2. 2) Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, Kusano K, Kobayashi Y, Koretsune Y, Sasano T, Sumitomo N, Takahashi N, Niwano S, Hagiwara N, Hisatome I, Furukawa T, Honjo H, Maruyama T, Murakawa Y, Yasaka M, Watanabe E, Aiba T, Amino M, Itoh H, Ogawa H, Okumura Y, Aoki-Kamiya C, Kishihara J, Kodani E, Komatsu T, Sakamoto Y, Satomi K, Shiga T, Shinohara T, Suzuki A, Suzuki S, Sekiguchi Y, Nagase S, Hayami N, Harada M, Fujino T, Makiyama T, Maruyama M, Miake J, Muraji S, Murata H, Morita N, Yokoshiki H, Yoshioka K, Yodogawa K, Inoue H, Okumura K, Kimura T, Tsutsui H, Shimizu W and Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group: JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. Circ J, 2022; 86: 1790-1924

3. 3) Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J and Takita A: Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes, 2022; 8: 202-213

4. 4) Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M and Antman EM: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013; 369: 2093-2104

5. 5) Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L and ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Safety and Effectiveness of a 4-Factor Prothrombin Complex Concentrate in Japanese Patients Experiencing Major Bleeding: A Post-marketing Surveillance Study;Cardiology and Therapy;2024-02-06